The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 17, 2009
Filed:
May. 24, 2004
Mary Collins, Natick, MA (US);
Ethan Menahem Shevach, Rockville, MD (US);
Rebecca Suzanne Mchugh, Wellington, NZ;
Matthew James Whitters, Hudson, MA (US);
Deborah Ann Young, Melrose, MA (US);
Michael Chapman Byrne, Brookline, MA (US);
Padmalatha S. Reddy, Walpole, MA (US);
Geoffrey Laurence Stephens, Damascus, MD (US);
Beatriz M. Carreno, Acton, MA (US);
Mary Collins, Natick, MA (US);
Ethan Menahem Shevach, Rockville, MD (US);
Rebecca Suzanne McHugh, Wellington, NZ;
Matthew James Whitters, Hudson, MA (US);
Deborah Ann Young, Melrose, MA (US);
Michael Chapman Byrne, Brookline, MA (US);
Padmalatha S. Reddy, Walpole, MA (US);
Geoffrey Laurence Stephens, Damascus, MD (US);
Beatriz M. Carreno, Acton, MA (US);
Wyeth, Madison, NJ (US);
The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC (US);
Abstract
The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.